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ABSTRACT
Objective: To develop and evaluate floating microspheres of repaglinide (RG).
Materials and Methods: RG loaded noneffervescent microspheres of different ratios of ethylcellulose (EC) and hydroxypropyl methylcellulose (HPMC 
K4M) were prepared using polyvinyl alcohol as emulsifier by solvent evaporation technique. Various process variables such as polymer ratio, stirring 
speed, concentration of drug, and emulsifying agent were studied. Compatibility of drug and polymers was studied by Fourier-transform infrared 
spectroscopy (FTIR). Characterization, in-vitro evaluation, and kinetic studies were performed.
Results: FTIR spectra have revealed no drug-excipient incompatibility. The average particle size of microspheres was in the range of 312-359 µm. The 
results showed that floating microspheres were successfully prepared with good yield (56.15-64.3%), high entrapment efficiency (58.22-70.14%), 
and good floating behavior (63.1-76.2%), respectively. In-vitro release data indicates appreciable amount of drug is released (62.28-73.27%) from the 
microspheres in gastric fluid. The mechanism of drug release founds to follow first order kinetics (r2=0.986).
Conclusion: The developed floating microspheres of RG may be used for prolonged drug release for at least 12 hrs, thereby improving bioavailability 
and patient compliance.
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INTRODUCTION
Diabetes mellitus is commonly occurring, one of the oldest and chronic 
noncommunicable disease. It is a serious, costly and heterogeneous 
metabolic disorder characterized by altered carbohydrate, lipid 
and protein metabolism [1]. Diabetes mellitus is the fourth or 
fifth leading cause of death in most developed countries with the 
substantial evidence to be epidemic in many developing and newly 
industrialized countries, affecting about 25% of the population [2]. 
Diabetes results in a state of chronic hyperglycemia (peripheral 
insulin resistance), glycosuria, polyuria, polydipsia (excessive thirst), 
polyphagia (constant hunger), sudden weight loss, ketoacidosis, 
ketonuria (urinary ketones), etc. [3]. Type II diabetes is referred to as 
insulin resistance, caused by greatly diminished sensitivity of target 
tissues to the metabolic effects of insulin. Type II diabetes accounts 
for 80-90% of all cases of diabetes. Type II diabetes is associated 
with increased plasma insulin concentration which occurs as a 
compensatory response by the pancreatic β-cells for the decrease 
in carbohydrate utilization and storage and the resultant increase in 
blood glucose [4].
Repaglinide (RG) is first member of meglitinide class and an oral 
hypoglycemic agent, used in the treatment of Type II diabetes mellitus. 
It binds to specific site on pancreatic β-cells, blocks the adenosine 
triphosphate-dependent potassium channel and thereby stimulates 
insulin release [5]. Due to low bioavailability (50%) and short half-life 
(1 hr) RG requires frequent dosing before meals and thus imposing 
various side effects such as skeletal muscles pain, headache, and 
gastrointestinal tract (GIT) effects [6]. To reduce these side effects and 
increase duration of action by controlling the release of drug slowly, the 
drug is encapsulated within polymeric membrane, thus maintain its 
concentration for longer duration and increase effectiveness. Therefore, 
the drug is suitable target for developing floating delivery system as it 
has the characteristics of short lasting action, fast clearance, enzymatic 
stability, and absorption throughout GIT. The objective of this research 
work was to develop multiparticulate floating drug delivery system of 
RG with ethylcellulose (EC) and hydroxypropyl methylcellulose (HPMC) 
K4M as release control polymer.
Oral route is the most preferred route having advantage of easy 
administration, handling, and patient convenience. Gastroretentive 
delivery systems are mainly designed for drugs having narrow 
absorption window. Such systems get retain at the site of absorption 
and release drug in controlled manner for longer time. Several such 
approaches were developed such as swelling and expanding systems, 
high-density systems, ion-exchange resin systems, bio/mucoadhesive 
systems, raft forming systems, superporous hydrogel systems, 
magnetic systems, bioadhesive liposomal systems, and modified shape 
systems [7]. Floating drug delivery system has drawn much attention 
nowadays due to buoyancy action having greater safety for clinical 
uses and having no effect of peristaltic movement of the GIT [8]. Drugs 
having short half-life require frequent dosing as they eliminated quickly 
from blood circulation, therefore, to increase the bioavailability [9] of 
such drugs controlled release formulations were prepared. Several 
categories of drugs having local action and primarily absorbed in the 
stomach, poorly soluble in alkaline pH, narrow absorption window, 
unstable in the intestine or colonic environment are suitable candidates 
for formulating as floating delivery system [10]. In the recent literature, 
various floating microspheres for encapsulation of different drugs such 
as rabeprazole sodium [11] and dextromethorphan hydrobromide [12] 
have been reported.
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MATERIALS AND METHODS
Materials
RG was procured as gift sample from Torrent Pharmaceuticals, 
Ahmedabad, India. EC and HPMC K4M were purchased from Himedia 
Chemicals, India. Ethanol, dichloromethane (DCM), and other solvents 
were purchased from SD Fine Chemicals Mumbai, India. All other 
chemicals used were of analytical grade.
Compatibility study
Compatibility study of drug and polymer was studied by Fourier-
transform infrared (FTIR) spectrophotometer (Shimadzu 8400, Japan) 
instrument. IR spectra of pure drug and mixture of drug with EC and 
HPMC K4M were analyzed and recorded.
Formulation of floating microspheres
Solvent diffusion evaporation technique with slight modification [13] 
was employed for preparation of formulations. Both the polymers were 
dissolved in mixture of dichloromethane (DCM) and ethanol (1:1). To 
this solution drug and 0.1% of polyethylene glycol was dispersed and 
stirred by means of high-speed mechanical stirrer (Remi Equipment, 
India) for 15 mins. The organic phase was then slowly poured into 80 ml 
of water containing 0.46% w/v of polyvinyl alcohol (PVA) (emulsifier) 
and stirred for 1 hr. Formulation design of microspheres is shown in 
Table 1. The microspheres were washed thoroughly with distilled 
water and dried for 1 hr at room temperature. Process variables such 
as polymer ratio, drug:polymer ratio, concentration of emulsifier, and 
stirring rate were studied during formulation.
Characterization of microspheres
Micromeritics properties
Microspheres were characterized for micromeritics properties such 
as particle size, tapped density, bulk density, and angle of repose. 
Particle size is measured using an optical microscopy and mean 
particle size was calculated by measuring 200-300 particles with 
calibrated ocular micrometer. Fixed funnel method is used to measure 
the flow characteristics. Tapped density was determined using tapping 
method [14].
Morphology
The shape and surface morphology of the microspheres were examined 
by scanning electron microscopy (SEM) (Jeol JSM-1600, Tokyo, Japan).
Floating behavior
50 µg of the microparticles were placed in SGF (pH 1.2, 100 ml) 
containing Tween 20 (0.02 w/v %) and stirred at 100 rpm. After 12 hrs 
buoyant and settled microparticles were separated, dried, and weighed. 
The buoyancy was calculated using following formula:
Buoyancy (%) = Wf/(Wf+WS) × 100
Where, Wf and Ws are the weights of the floating and settled 
microparticles, respectively.
Entrapment efficiency and yield
To 10 ml of ethanol, 50 µg of microparticles were crushed, suspended and 
was kept for 12 hrs for extraction of drug. RG content was determined 
from the filtrate after suitable dilution spectrophotometrically at 
247 nm. The percentage drug entrapment and yield [15] were calculated 
as follows:
% Drug entrapment = (Calculated drug content/Theoretical drug 
content) × 100
% Yield = (Total weight of floating microparticles/Total weight of drug 
and polymer) × 100
In-vitro drug release studies
In-vitro dissolution study was carried out in a paddle type six-station 
dissolution test apparatus (Veego, VDA-6DR, and USP Std.). Floating 
microspheres equivalent to 16 µg of the drug were placed in 0.1 N HCl 
(1.2 pH) containing Tween 20 (0.02 w/v%) maintained at 37±0.5°C at 
a rotation speed of 100 rpm. Perfect sink condition was maintained. 
1 ml sample was withdrawn after every hr, filtered and analyzed 
spectrophotometrically at 247 nm. All experiments were conducted in 
triplicate.
Evaluation of in-vitro release kinetics
The kinetics of drug release can be known by substituting the in-vitro 
release data to different kinetic models such as zero order (% cum. drug 
retained vs. t), first order (log % cum. drug release vs. t), Higuchi model 
(% cum. drug release vs. square root of time), and Peppas exponential 
equation (log % cum. drug release vs. log time). Regression coefficient 




Interaction of drug and polymers were studied by FTIR and 
spectra’s were shown in Fig. 1. Spectra of RG shows peaks at 3308 
(NH stretching), 2947 (CH stretching), 1220 (CH3), and 1685cm-1 
(C=O). Spectra of EC show a sharp band at 2929 and 3481cm-1 
associated with a CH and OH stretching vibrations, respectively. 
Spectra of HPMC K4M show band at 3295 and 2931cm-1 of OH and 
CH stretching vibrations, along with ethereal C-O-C group stretching 
vibration between 1192 and 1073cm-1. IR spectra of mixture of drug 
with EC and HPMC K4M shows peaks at 3308cm-1 (NH stretching), 
2934cm-1 (CH stretching), and 1687cm-1 (C=O) thereby, having no 
interaction, as there was no major shift in the absorption bands of 
drug was found.
Formation of microspheres
The floating microspheres were prepared by solvent diffusion 
evaporation technique using EC and HPMC K4M polymers. Organic 
phase containing suspension of polymer and drug in 1:1 ratio of ethanol 
and DCM was poured into an aqueous phase containing PVA. The 
organic solvents get rapidly distributed into the external aqueous phase 
Table 1: Formulation and optimization of microspheres
Batch code Ratio of EC:HPMC Concentration of emulsifying agent (%) Stirring rate (rpm) Amount of drug (µg)
C1 1:1 0.46 900 10
C2 1:2 0.46 900 10
C3 1:3 0.46 900 10
C4 1:2 0.46 600 10
C5 1:2 0.46 1200 10
C6 1:2 0.66 900 10
C7 1:2 0.86 900 10
C8 1:2 0.46 900 20
C9 1:2 0.46 900 30
EC: Ethylcellulose, HPMC: Hydroxypropyl methylcellulose
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and microspheres were formed by precipitation of polymer around the 
drug particle due to the evaporation of organic phase [15].
Micromeritics properties
The micromeritics properties were evaluated for all the batches of the 
microspheres. The angle of repose values ranged between 31.81±1.11 
and 39.85±2.84 indicating good flow characteristics. The bulk and 
tapped density were found in the range of 0.64±0.45 to 0.70±0.36 and 
0.83±0.25 to 0.87±0.35 g/cm3, respectively, (Table 2) indicating the 
nonaggregated nature of prepared microspheres.
Morphology
SEM photographs reveal the spherical orientation with smooth and 
dense outer surface of microspheres prepared as shown in Fig. 2. The 
ruptured surface showing hollow nature of microspheres in the interior 
which makes them to float on the GIT fluid.
Floating behavior, drug entrapment, and yield
Flow ability was observed by calculating percent buoyancy and was 
found that more than 63.18% microspheres remained floating at the end 
of 12 hrs. Increase in concentration of HPMC K4M increases buoyancy. 
Increase in stirring rate from 600 to 1200 decreases buoyancy from 
75.1% to 67.2% due to reduction in size of the particle at high-speed 
of rotation. Percent yield was >56.1% for all the formulations and 
it decreases with increase of HPMC K4M concentration may be due 
to migration of hydrophilic polymer into continuous phase forming 
agglomerates. On increasing stirring speed from 600 to 900 rpm % 
yield increases (59.24-67.41%), whereas on further increase in speed 
of rotation to 1200 rpm it decreases [17]. Figs. 3 and 4 show the effect 
of stirring rate and concentration of emulsifier on various parameters 
studied. No significant effect of increasing emulsifier concentration on 
percentage yield was observed.
Fig. 3: Effect of stirring rate on various optimization parameters. 
All data are represented as mean±standard deviation (n=3)
Fig. 1: Infrared spectra: (a) Repaglinide (RG), (b) hydroxypropyl methylcellulose (HPMC) K4M, (c) mixture of RG and HPMC K4M, 






Fig. 2: Scanning electron microscopy images: (a) Spherical shaped 
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The value of entrapment efficiency ranged from 58.22% to 70.15% 
for all the formulation. The high entrapment of RG was found to be 
due to its poor water solubility. The extent of loading influenced 
the particle size distribution of microspheres. Increasing polymer 
concentrations slightly increases drug loading. Increase in stirring 
speed from 600 to 900 rpm (64.15-67.18%) increases entrapment, 
which decreases as stirring speed increased to 1200 rpm, which 
is due to reduced size of microspheres formed at higher speed of 
rotation [18].
In-vitro drug release and kinetic studies
Release of drug from prepared formulations was evaluated in pH 1.2 
for 12 hrs. Release of drug from any of the formulation has no burst 
effect, hence showing homogenous drug distribution. Not much effect 
on release was observed with increasing HPMC K4M polymer because 
of less hydration of high viscosity polymer.
On increasing speed of rotation from 600 to 1200 rpm, there is an 
increase in drug release from 64.31-72.41%. As the particle size is 
reduced due to increased stirring, large surface area is exposed to 
release. Increase in concentration of drug has no significant effect on 
drug release. On the basis of good results of buoyancy, drug content, 
size, yield and release C2 was selected as optimized formulation.
The data obtained for in-vitro release were fitted into equations for 
the zero order, first order, Higuchi, and Peppas model. The data were 
interpreted on the bases of regression coefficients obtained. In-vitro 
release data of optimized formulation follows first order kinetics 
(r2=0.986) (Fig. 5) followed by Peppas and Higuchi model. Peppas 
equation has been applied to explain the release mechanism. Value of 
slope (n) was calculated and is ≤0.89, showing coupling of diffusion and 
erosion mechanism called anomalous diffusion, indicating that drug 
release is controlled by more than one process. From these results, it 
can be concluded that release of drug follows first order, diffusion, and 
erosion mechanism.
CONCLUSION
The formulation of RG loaded EC and HPMC K4M microspheres 
were successfully prepared. Different investigations on formulation, 
characterization, in-vitro release, and kinetic study were carried out. 
The development of formulation and optimization yielded the desired 
microspheres with drug release up to 12 hrs and with advantage of 
floatability in gastric juice for prolonged time. The proposed optimized 
formulation depicts an effective way to prolongs drug release which are 
safe and in need of pharmaceutical industry as an alternate for effective 
management of noninsulin-dependent diabetes mellitus.
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